Literature DB >> 8723487

Differences in the resistant variants of Enterobacter cloacae selected by extended-spectrum cephalosporins.

J C Fung-Tomc1, E Gradelski, E Huczko, T J Dougherty, R E Kessler, D P Bonner.   

Abstract

The rates of development of resistance to ceftriaxone, ceftazidime, cefepime, and cefpirome in 10 strains of Enterobacter cloacae were determined by daily transfer for 7 days to fresh medium containing twofold serial dilutions of the antibiotics. Development of resistance to ceftriaxone was the most rapid; this was followed by ceftazidime, cefpirome, and cefepime. Resistant variants selected by ceftriaxone and ceftazidime were cross-resistant and produced very high levels of beta-lactamase. On the other hand, resistant variants selected by cefepime and cefpirome often had moderately high levels of beta-lactamase and diminished levels of the 39- to 40-kDa porin protein.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8723487      PMCID： PMC163312          DOI： 10.1128/AAC.40.5.1289

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  28 in total

Review 1.  A functional classification scheme for beta-lactamases and its correlation with molecular structure.

Authors:  K Bush; G A Jacoby; A A Medeiros
Journal:  Antimicrob Agents Chemother       Date:  1995-06       Impact factor: 5.191

2.  Development of resistance during ceftazidime and cefepime therapy in a murine peritonitis model.

Authors:  J C Pechère; I R Vladoianu
Journal:  J Antimicrob Chemother       Date:  1992-05       Impact factor: 5.790

Review 3.  Factors involved in the enhanced efficacy against gram-negative bacteria of fourth generation cephalosporins.

Authors:  R E Hancock; F Bellido
Journal:  J Antimicrob Chemother       Date:  1992-04       Impact factor: 5.790

4.  Association of two resistance mechanisms in a clinical isolate of Enterobacter cloacae with high-level resistance to imipenem.

Authors:  E H Lee; M H Nicolas; M D Kitzis; G Pialoux; E Collatz; L Gutmann
Journal:  Antimicrob Agents Chemother       Date:  1991-06       Impact factor: 5.191

5.  Development of resistance in Pseudomonas aeruginosa to broad-spectrum cephalosporins via step-wise mutations.

Authors:  E Gradelski; J Fung-Tomc; E Huczko; R E Kessler
Journal:  J Antimicrob Chemother       Date:  1993-11       Impact factor: 5.790

6.  beta-Lactamase expression and outer membrane protein changes in cefpirome-resistant and ceftazidime-resistant gram-negative bacteria.

Authors:  L J Piddock; E A Traynor
Journal:  J Antimicrob Chemother       Date:  1991-08       Impact factor: 5.790

7.  Activity of carbapenem BMS-181139 against Pseudomonas aeruginosa is not dependent on porin protein D2.

Authors:  J C Fung-Tomc; E Gradelski; B Kolek; B Minassian; M Pucci; R E Kessler; D P Bonner
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191

8.  Development of multiple-antibiotic-resistant (Mar) mutants of Pseudomonas aeruginosa after serial exposure to fluoroquinolones.

Authors:  G G Zhanel; J A Karlowsky; M H Saunders; R J Davidson; D J Hoban; R E Hancock; I McLean; L E Nicolle
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191

9.  Trends in antibiotic utilization and bacterial resistance. Report of the National Nosocomial Resistance Surveillance Group.

Authors:  C H Ballow; J J Schentag
Journal:  Diagn Microbiol Infect Dis       Date:  1992-02       Impact factor: 2.803

10.  Resistance to cefotaxime and seven other beta-lactams in members of the family Enterobacteriaceae: a 3-year survey in France.

Authors:  D L Sirot; F W Goldstein; C J Soussy; A L Courtieu; M O Husson; J Lemozy; M Meyran; C Morel; R Perez; C Quentin-Noury
Journal:  Antimicrob Agents Chemother       Date:  1992-08       Impact factor: 5.191
View more
  10 in total

Review 1.  Achieving an optimal outcome in the treatment of infections. The role of clinical pharmacokinetics and pharmacodynamics of antimicrobials.

Authors:  R C Li; M Zhu; J J Schentag
Journal:  Clin Pharmacokinet       Date:  1999-07       Impact factor: 6.447

2.  Comparative killing rates of fluoroquinolones and cell wall-active agents.

Authors:  J C Fung-Tomc; E Gradelski; L Valera; B Kolek; D P Bonner
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

3.  ampR gene mutations that greatly increase class C beta-lactamase activity in Enterobacter cloacae.

Authors:  A Kuga; R Okamoto; M Inoue
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

Review 4.  The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria.

Authors:  Xian-Zhi Li; Patrick Plésiat; Hiroshi Nikaido
Journal:  Clin Microbiol Rev       Date:  2015-04       Impact factor: 26.132

Review 5.  A Primer on AmpC β-Lactamases: Necessary Knowledge for an Increasingly Multidrug-resistant World.

Authors:  Pranita D Tamma; Yohei Doi; Robert A Bonomo; J Kristie Johnson; Patricia J Simner
Journal:  Clin Infect Dis       Date:  2019-09-27       Impact factor: 9.079

Review 6.  Cefpirome. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy in the treatment of severe nosocomial infections and febrile neutropenia.

Authors:  L R Wiseman; H M Lamb
Journal:  Drugs       Date:  1997-07       Impact factor: 9.546

7.  Comparison of Ceftriaxone and Antipseudomonal β-Lactam Antibiotics Utilized for Potential AmpC β-Lactamase-Producing Organisms.

Authors:  David M Peters; Jessica B Winter; Christopher A Droege; Neil E Ernst; Siyun Liao
Journal:  Hosp Pharm       Date:  2020-06-04

8.  Selection during cefepime treatment of a new cephalosporinase variant with extended-spectrum resistance to cefepime in an Enterobacter aerogenes clinical isolate.

Authors:  G Barnaud; Y Benzerara; J Gravisse; L Raskine; M J Sanson-Le Pors; R Labia; G Arlet
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

Review 9.  Anti-pseudomonal beta-lactams for the initial, empirical, treatment of febrile neutropenia: comparison of beta-lactams.

Authors:  Mical Paul; Dafna Yahav; Assaf Bivas; Abigail Fraser; Leonard Leibovici
Journal:  Cochrane Database Syst Rev       Date:  2010-11-10

Review 10.  Use of Antimicrobials for Bloodstream Infections in the Intensive Care Unit, a Clinically Oriented Review.

Authors:  Alexis Tabah; Jeffrey Lipman; François Barbier; Niccolò Buetti; Jean-François Timsit
Journal:  Antibiotics (Basel)       Date:  2022-03-08
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.